Brief: Qurient Announces Dosing Of First Patient In Q901 Phase 1/2 Clinical Study For The Treatment Of Patients With Solid Tumors
01/12/2022 14:10
Dec 1 (Reuters) - Qurient Co Ltd 115180.KQ :
* QURIENT ANNOUNCES DOSING OF FIRST PATIENT IN Q901 PHASE
1/2
CLINICAL STUDY FOR THE TREATMENT OF PATIENTS WITH SOLID TUMORS
Source text for Eikon: ID:nBwbr2NQba
Further company coverage: 115180.KQ
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Qurient
See all newsBrief: Lonza Expands Dual-Payload ADC Technology Offering Through Access To Qurient's CDK7 Inhibitors
Brief: Qurient To Conduct Capital Increase Of 8 Billion Won For Operational Funds
Brief: Qurient Therapeutics Enters Crada With The National Cancer Institute To Collaborate On A Phase 1/2 Clinical Study Of Q901 In Combination With Trop2-Adc
Brief: Qurient Announces Dosing Of First Patient In Q901 Phase 1/2 Clinical Study For The Treatment Of Patients With Solid Tumors
Brief: Qurient Announces Collaboration Agreement With MSD